Revvity, Inc. (NYSE:RVTY) reported better-than-expected fourth-quarter results on Monday, with both earnings and revenue coming in ahead of market forecasts.
The company posted adjusted earnings per share of $1.70 for the quarter, comfortably above analyst expectations of $1.55. Revenue reached $772.06 million, also exceeding the consensus estimate of $758.53 million. Revvity shares rose 1.05% in premarket trading following the announcement.
Fourth-quarter revenue increased 6% from $729 million a year earlier, supported by 4% organic growth. On a GAAP basis, earnings per share rose to $0.87 from $0.78 in the same period last year.
“We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations,” said Prahlad Singh, president and chief executive officer of Revvity. “Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come.”
Growth was led by the Diagnostics segment, where revenue climbed 10% to $390 million, including 7% organic growth. The Life Sciences segment posted a more modest performance, with revenue rising 2% to $382 million, while organic revenue was flat compared with the prior-year quarter.
For the full year 2025, Revvity reported adjusted earnings per share of $5.06, up from $4.90 in 2024. Total revenue for the year increased to $2.86 billion from $2.76 billion previously.
Looking ahead, the company issued its first outlook for fiscal 2026, forecasting revenue in a range of $2.96 billion to $2.99 billion, ahead of the analyst consensus of $2.94 billion. Adjusted earnings per share are expected to come in between $5.35 and $5.45, also above the consensus estimate of $5.32.
Adjusted operating margin for the fourth quarter stood at 29.7%, slightly lower than the 30.3% recorded a year earlier, reflecting continued investment in the business despite solid top-line growth.